Article info

Download PDFPDF

Novel treatments for novel side effects: a case report and review of baricitinib use in the treatment of chronic inflammatory demyelinating polyneuropathy caused by immune checkpoint inhibitor use

Authors

  • Sana Haider Ingham Institute, Liverpool, New South Wales, AustraliaSchool of Medicine, Western Sydney University, Campbelltown, New South Wales, Australia PubMed articlesGoogle scholar articles
  • Wei Chua School of Medicine, Western Sydney University, Campbelltown, New South Wales, AustraliaIngham Institute for Applied Medical Research, Liverpool, New South Wales, AustraliaDepartment of Medical Oncology, Liverpool Hospital, Liverpool, New South Wales, Australia PubMed articlesGoogle scholar articles
  • Bavanthi Balakrishnar Department of Medical Oncology, Liverpool Hospital, Liverpool, New South Wales, Australia PubMed articlesGoogle scholar articles
  • Stephen Della-Fiorentina Immunology and Allergy Unit, Department of Medicine, Campbelltown Hospital, Campbelltown, New South Wales, Australia PubMed articlesGoogle scholar articles
  • Tara Laurine Roberts School of Medicine, Western Sydney University, Campbelltown, New South Wales, AustraliaIngham Institute for Applied Medical Research, Liverpool, New South Wales, Australia PubMed articlesGoogle scholar articles
  • Karuna Keat School of Medicine, Western Sydney University, Campbelltown, New South Wales, AustraliaIngham Institute for Applied Medical Research, Liverpool, New South Wales, AustraliaImmunology and Allergy Unit, Department of Medicine, Campbelltown Hospital, Campbelltown, New South Wales, Australia PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Sana Haider; sana_haider{at}outlook.com
View Full Text

Citation

Haider S, Chua W, Balakrishnar B, et al
Novel treatments for novel side effects: a case report and review of baricitinib use in the treatment of chronic inflammatory demyelinating polyneuropathy caused by immune checkpoint inhibitor use

Publication history

  • Accepted October 24, 2023
  • First published November 21, 2023.
Online issue publication 
November 21, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.